Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study

1. Weitz TA, Foster A, Ellertson C, Grossman D, Stewart FH. "Medical" and "surgical" abortion: rethinking the modifiers. Contraception. 2004;69(1):77–8. 14720625

2. Winikoff B, Westhoff C. Fifteen years: looking back and looking forward. Contraception. 2015;92(3):177–8. doi: 10.1016/j.contraception.2015.06.019 26142617

3. Greene MF, Drazen JM. A New Label for Mifepristone. N Engl J Med. 2016;374(23):2281–2. doi: 10.1056/NEJMe1604462 27276566

4. World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG. 2000;107(4):524–30. 10759273

5. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998;338(18):1241–7. 9562577

6. Kulier R, Kapp N, Gulmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. The Cochrane database of systematic reviews. 2011;(11):Cd002855. doi: 10.1002/14651858.CD002855.pub4

7. World Health Organization. Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. Bmj. 1993;307(6903):532–7. 8400972

8. Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol. 2000;183(2 Suppl):S44–53. 10944369

9. Ngo TD, Park MH, Shakur H, Free C. Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review. Bulletin of the World Health Organization. 2011;89(5):360–70. doi: 10.2471/blt.10.084046 21556304

10. Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception. 2000;61(1):41–6. 10745068

11. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002;66(4):247–50. 12413620

12. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001;64(2):81–5. 11704083

13. Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health. 2003;35(1):16–24. 12602753

14. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion. Obstet Gynecol. 2005;106(4):871–82. 16199653

15. Winikoff B, Dzuba IG, Chong E, Goldberg AB, Lichtenberg ES, Ball C, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012;120(5):1070–6. doi: http://10.1097/AOG.0b013e31826c315f 23090524

16. Sanhueza Smith P, Pena M, Dzuba IG, Garcia Martinez ML, Arangure Peraza AG, Bousieguez M, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reprod Health Matters. 2015;22(44 Suppl 1):75–82. doi: 10.1016/S0968-8080(15)43825-X 25702071

17. Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015;91(4):269–73. doi: 10.1016/j.contraception.2015.01.005 25592080

18. American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676–92. doi: 10.1097/01.AOG.0000444454.67279.7d 24553166

19. Winikoff B, Dzuba IG, Creinin MD, Crowden WA, Goldberg AB, Gonzales J, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol. 2008;112(6):1303–10. doi: 10.1097/AOG.0b013e31818d8eb4 19037040

20. National Abortion Federation. NAF Protocol for Mifepristone/Misoprostol in Early Abortion in the U.S. 2010. http://prochoice.org/wp-content/uploads/protocol_mife_miso.pdf.

21. World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva, Switzerland: 2012. http://www.who.int/reproductivehealth/publications/unsafe_abortion/9789241548434/en/.

22. Radley DC, Finkelstein SN, Stafford RS. OFf-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–6. doi: 10.1001/archinte.166.9.1021 16682577

23. U.S. Food and Drug Administration. "Off-Label" and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices—Information Sheet. 1998.

24. U.S. Food and Drug Administration. Mifeprex (mifepristone) Information. Postmarket Drug Safety Information for Patients and Providers: 2016. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111323.htm.

25. Boonstra HD. Medication Abortion Restrictions Burden Women and Providers—and Threaten U.S. Trend Toward Very Early Abortion. Guttmacher Policy Review. 2013;(1).

26. ND HB 1297, Legislative Assembly of North Dakota (2011). http://www.legis.nd.gov/assembly/62-2011/bill-index/bi1297.html.

27. TX HB2, Texas State of Representatives (2013). http://www.legis.state.tx.us/BillLookup/History.aspx?LegSess=832&Bill=HB2.

28. Associated Press. New abortion drug label could undo several state laws. March 30, 2016. http://www.modernhealthcare.com/article/20160330/NEWS/303309998.

29. Upadhyay UD, Desai S, Zlidar V, Weitz TA, Grossman D, Anderson P, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol. 2015;125(1):175–83. doi: 10.1097/AOG.0000000000000603 25560122

30. Haimov-Kochman R, Arbel R, Sciaky-Tamir Y, Brzezinski A, Laufer N, Yagel S. Risk factors for unsuccessful medical abortion with mifepristone and misoprostol. Acta Obstet Gynecol Scand. 2007;86(4):462–6. doi: 10.1080/00016340701203632 17486469

31. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983–97. 9333350

32. Loomis D, Richardson DB, Elliott L. Poisson regression analysis of ungrouped data. Occupational and environmental medicine. 2005;62(5):325–9. doi: 10.1136/oem.2004.017459 15837854

33. Bureau of Labor Statistics. Consumer Price Index for Medical Care. 2015.

34. Sheldon WR, Winikoff B. Mifepristone Label Laws and Trends in Use: Recent Experiences in Four U.S. States. Contraception. 2015. doi: 10.1016/j.contraception.2015.06.017

35. Grossman D, Baum S, Fuentes L, White K, Hopkins K, Stevenson A, et al. Change in abortion services after implementation of a restrictive law in Texas. Contraception. 2014;90(5):496–501. doi: 10.1016/j.contraception.2014.07.006 25128413

36. Pazol K, Creanga AA, Burley KD, Jamieson DJ. Abortion surveillance—United States, 2011. MMWR Surveill Summ. 2014;63(11):1–41. 25426741

37. Jones RK, Jerman J. Abortion Incidence and Service Availability In the United States, 2011. Perspect Sex Reprod Health. 2014. doi: 10.1363/46e0414

38. Lupfer M, Silber BG. How patients view mandatory waiting periods for abortion. Fam Plann Perspect. 1981;13(2):75–9. 7250344

39. Ludden J. Abortion Restrictions Complicate Access For Ohio Women. NPR. 2015 March 3.

40. Gross A. John Kasich’s Quiet Campaign To Cut Abortion Access. FiveThirtyEight. 2015 December 2, 2015. http://fivethirtyeight.com/features/john-kasichs-quiet-campaign-to-cut-abortion-access/.

41. World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Lowering the doses of mifepristone and gameprost for early abortion: a randomised controlled trial. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation. BJOG. 2001;108(7):738–42. 11467701

42. Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol. 2005;123(1):87–91. doi: 10.1016/j.ejogrb.2005.02.019 16260342

43. el-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med. 1995;332(15):983–7. doi: 10.1056/nejm199504133321502 7885426

44. Honkanen H, Piaggio G, Hertzen H, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. BJOG. 2004;111(7):715–25. doi: 10.1111/j.1471-0528.2004.00153.x 15198763

45. Ginde AA, Lowe RA, Wiler JL. Health insurance status change and emergency department use among US adults. Archives of Internal Medicine. 2012;172(8):642–7. doi: 10.1001/archinternmed.2012.34 22450213

46. Sandoval E, Smith S, Walter J, Schuman SAH, Olson MP, Striefler R, et al. A Comparison of Frequent and Infrequent Visitors to an Urban Emergency Department. J Emerg Med. 2010;38(2):115–21. doi: 10.1016/j.jemermed.2007.09.042 18462906

47. U.S. Department of Health & Human Services. Health Insurance Coverage and the Affordable Care Act. 2015.

48. Siegel J, Candinsky C. Medicaid expansion funding gets approval. The Columbus Dispatch. October 21, 2013. http://www.dispatch.com/content/stories/local/2013/10/21/Medicaid-expansion-vote.html.

49. U.S. Department of Health & Human Services. Key Features of the Affordable Care Act By Year. http://www.hhs.gov/healthcare/facts-and-features/key-features-of-aca-by-year/index.html. 2015.

50. House Bill Number 79, General Assembly of the State of Ohio (2012). http://archives.legislature.state.oh.us/bills.cfm?ID=129_HB_79_PS.

51. Redden M. Abortion without the clinic on offer with revolutionary new US program. The Guardian. 2016 March 31, 2016. http://www.theguardian.com/world/2016/mar/31/new-us-program-abortion-without-clinic-mifepristone-mifeprex.

52. Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine [Internet]. National Library of Medicine. 2016. https://clinicaltrials.gov/ct2/show/NCT02513043.

53. Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation [Internet]. National Library of Medicine. 2016. https://clinicaltrials.gov/ct2/show/NCT02314754.